Dr.Reddy's Laboratories Ltd (RDY.N)
MUMBAI India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.
BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier
* Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn
|Cipla Ltd (CIPL.NS)||Rs527.40||+6.75|
|GlaxoSmithKline plc (GSK.L)||1,688.00p||-11.50|
|Ranbaxy Laboratories Limited (RANB.NS)||Rs859.80||--|
|Piramal Enterprises Ltd (PIRA.NS)||Rs1,607.05||-1.60|
|Sun Pharmaceutical Industries Limited (SUN.NS)||Rs829.95||+4.50|
|Sun Pharmaceutical Industries Limited (SUN_p.NS)||--||--|
|Lupin Limited (LUPN.NS)||Rs1,739.85||+34.90|
|Richter Gedeon Vegyeszeti Gyar Nyrt (GDRB.BU)||--||--|
|Krka d.d. Novo Mesto (KRKG.LJ)||€59.50||--|
|Pliva d.d. (PLV.ZA)||--||--|
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Provider : Wright Reports
"The Economy Matters" Report for RDY: the economy's impact on RDY's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider : MacroRisk Analytics/EconomicInvestor
Provider : ValuEngine, Inc.
Dr.Reddy's Laboratories Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.